Ikonisys becomes distributor of oncoFISH cancer test
This article was originally published in Clinica
Ikonisys has become the distributor of Clinical Laboratory Partners’ oncoFISH cervical cancer test as part of an exclusive licensing deal. The assay is a companion test designed to work alongside existing cervical cancer screening tests like Pap smear and HPV tests prior to colposcopy. Under the terms of the partnership, Newington, Connecticut-based Clinical Laboratory Partners will market the assay to physicians for the analysis of specimens from liquid-based Pap tests classified as low-grade squamous intraepithelial lesion (LSIL). Ikonisys (New Haven, Connecticut) will conduct the evaluation of the specimen using its Ikoniscope digital microscopy system. The oncoFISH test will assist in determining if there is a risk of progression to cervical cancer or if the lesion will naturally regress, by identifying a genetic marker linked to increased likelihood of cervical cancer.